FRANKFURT (Reuters) - German drugmaker Bayer is in talks to sell its diabetes devices division but a sale is not imminent, two sources with knowledge of the matter told Reuters.
Bayer is making a second attempt to sell the Contour blood glucose-meter business, which had annual sales of 722 million euros ($819 million) in 2013, as it overhauls its business to focus on margin-rich healthcare sectors.
09:59 Spanish banks up provisions as mortgage floor hit tops 3 bln euros18
21:52 Netflix nears 94 million subscribers 10 years after streaming launch20
16:50 Goldman Sachs, Citigroup earnings confirm Trump effect on banks19
11:20 PE firm Warburg buys $121 million stake in Indian cinema operator PVR16